Investor Relations
Keep track with the latest news and press releases
Glucotrack, Inc. (NASDAQ: GCTK), is focused on the design, development, and commercialization of novel technologies for people with diabetes and prediabetes. The Company is currently developing a long-term implantable continuous glucose monitoring system for people living with diabetes.
gluconews
Sign up to our newsletter and be the first to know our latest developments
Recent News
GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION
Continuous blood glucose monitor’s preclinical data and sensor longevity modeling to be presented at major diabetes conference Rutherford, NJ, May 02, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been …
GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT
Rutherford, NJ, April 22, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that the Company has closed a private placement of securities. The Offering included participation by CEO Paul V. Goode, PhD, as …